Magnetic drug targeting: New paths to local drug accumulation in head and neck cancer;Magnetisches drug-targeting: Neue wege zur lokalen wirkstoffanreicherung in kopf- und halskarzinomen

HNO

Volumn 53, Issue 7, 2005, Pages 600-601

  Simon, C ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME; MITOXANTRONE;

ADVANCED CANCER; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; DRUG DELIVERY SYSTEM; DRUG TARGETING; HEAD AND NECK CARCINOMA; HUMAN; LARYNX CARCINOMA; NASOPHARYNX CARCINOMA; SHORT SURVEY;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; MAGNETICS; MITOXANTRONE; NEOPLASM TRANSPLANTATION; OTORHINOLARYNGOLOGIC NEOPLASMS; RABBITS; TREATMENT OUTCOME;

EID: 23844464763     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-005-1278-2     Document Type: Short Survey

References (16)

1. Alexiou C, Arnold W, Klein RJ et al. (2000) Locoregional cancer treatment with magnetic drug targeting. Cancer Res 60:6641-6648
2. Alexiou C, Jurgons R, Schmid RJ et al. (2003) Magnetic drug targeting - biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target 11:139-149
3. Alexiou C, Jurgons R, Schmid RJ, Erhardt W, Parak F, Bergemann C, Iro H (2004) Magnetic Drug Targeting - a new approach in locoregional tumor therapy with chemotherapeutic agents. Experimental animal studies. HNO (in press)
4. Arbab AS, Jordan EK, Wilson LB, Yocum GT, Lewis BK, Frank JA (2004) In vivo trafficking and targeted delivery of magnetically labeled stem cells. Hum Gene Ther 15:351-360
5. Bernier J, Domenge C, Ozsahin M et al. (2004) Post-operative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945-1952
6. Forastiere AA, Goepfert H, Maor M et al. (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098
7. Ito A, Kuga Y, Honda H, Kikkawa H, Horiuchi A, Watanabe Y, Kobayashi T (2004) Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Lett 212:167-175
8. Kharkevich DA, Alyautdin RN, Filippov VI (1989) Employment of magnet-susceptible microparticles for the targeting of drugs. J Pharm Pharmacol 41:286-288
9. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T (2000) Targeted delivery of anticancer drugs with intravenously administered magnetic liposomes in osteosarcoma-bearing hamsters, Int J Oncol 17:309-315
10. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T (2001) Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters, Int J Oncol 18:121-125
11. Leakakos T, Ji C, Lawson G, Peterson C, Goodwin S (2003) Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother Pharmacol 51:445-450
12. Lubbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, Huhn D (1996) Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res 56:4694-4701
13. Lubbe AS, Bergemann C, Riess H et al. (1996) Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 56:4686-4693
14. Nobuto H, Sugita T, Kubo T, Shimose S, Yasunaga Y, Murakami T, Ochi M (2004) Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet, Int J Cancer 109:627-635
15. Widder KJ, Senyei AE, Ranney DF (1980) In vitro release of biologically active adriamycin by magnetically responsive albumin microspheres. Cancer Res 40:3512-3517
16. Widder KJ, Morris RM, Poore G, Howard DP Jr, Senyei AE (1981) Tumor remission in Yoshida sarcoma-bearing rats by selective targeting of magnetic albumin microspheres containing doxorubicin. Proc Natl Acad Sci U S A 78:579-581